CTRI/2022/11/047612尚未招募未知
Efficacy & Safety of Insulin Glargine Co-administration in management of Paediatric Diabetic Ketoacidosis
Aster Intramural funding0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Males or females presenting with a known history of or presumed new onset type 1 diabetes with diabetic ketoacidosis.
- •Diabetic ketoacidosis is defined as serum glucose more than 200 mg/dl, venous pH less than 7.3 or serum bicarbonate less than 15mmol/l, ketonemia which is blood beta-hydroxybutyrate levels more than or equal to 3mmol/l or moderate to large ketonuria
排除标准
- •Participants who have begun insulin treatment prior to being approached for enrolment
- •Participants with known diagnosis of type2 diabetes, other specific types such as monogenic diabetes, genetic defects in insulin action, diseases of exocrine pancreas, endocrinopathies, drug or chemical induced insulin resistance and deficiency
- •Other genetic syndromes associated with diabetes
研究者
相似试验
招募中
不适用
Comparison of efficacy and safety of insulin glargine U-100/lixisenatide and insulin degludec/liraglutide in type 2 diabetes patientstype 2 Diabetes mellitusJPRN-UMIN000047518Minami Osaka Hospital36
已完成
不适用
Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Degludec in Patients with Type 2 Diabetes: A Randomized, Open-Label, Crossover Study Using Continuous Glucose Monitoring ProfilesdiabetesJPRN-UMIN000031044Minamiosaka Hospital30
已完成
不适用
Efficacy and safety of insulin glargine 300 U/ml versus 100 U/ml in type 2 diabetic patients treated with basal insulin plus GLP-1 receptor agonisttype 2 diabetesJPRN-UMIN000019353Shiraiwa Medical Clinic30
已完成
不适用
Efficacy and safety of insulin glargine 300 U/ml versus 100 U/ml in type 2 diabetic patients treated with basal insulin plus oral hypoglycemic agentstype 2 diabetesJPRN-UMIN000019354Shiraiwa Medical Clinic60
招募中
不适用
Efficacy and safety of once daily insulin glargine therapy for people with type 2 diabetes inadequately controlled with DPP4 inhibitor and several OADsType 2 DiabetesJPRN-UMIN000007375Tokyo Medical University100